Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis

doi:10.1007/s00109-019-01761-5

Paper

Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis

Published Feb 28, 2019 · S. Yadav, Devika Soin, Kouichi Ito

Journal of Molecular Medicine

Q1 SJR score

59

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Dimethyl fumarate (DMF) is an oral, disease-modifying agent for the treatment of relapsing–remitting multiple sclerosis (RRMS). However, details regarding its mode of action are still emerging. It is believed that the mode of action of DMF involves both nuclear factor erythroid-derived 2-related factor (Nrf2)–dependent and independent pathways, which lead to an anti-inflammatory immune response due to type II myeloid cell and Th2 cell differentiation and neuroprotection. In this review, we will focus on the molecular and signaling effects of DMF that lead to changes in peripheral immune cell composition and function, alteration in CNS cell-specific functions, and effect on the blood-brain barrier.

Study Snapshot

Dimethyl fumarate (DMF) treats multiple sclerosis by promoting anti-inflammatory immune responses and neuroprotection through type II myeloid cell and Th2 cell differentiation and blood-brain barrier disruption.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis

References

Citations